In 2021, Susan Bobulsky sat down with Dr. Luciano Costa to learn about the initial results from the phase 2 MRD response-Adapted Sequential ThERapy (MASTER) trial. The trial evaluated daratumumab (Darzalex), carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Dara-KRd) as induction therapy in patients with newly diagnosed multiple myeloma (MM), followed by autologous stem cell transplant (ASCT) and […] The post Clinically Actionable Insights: A Q&A with Dr.